Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$95.50 USD

95.50
1,324,649

+1.07 (1.13%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $95.51 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Zacks Equity Research

GILD or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GILD vs. ILMN: Which Stock Is the Better Value Option?

Zacks Equity Research

Why Illumina (ILMN) Could Be an Impressive Growth Stock

by Zacks Equity Research

If you are looking for a fast growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Illumina (ILMN).

Zacks Equity Research

Illumina, Wix.com, Microsoft, Facebook and Oracle highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Illumina, Wix.com, Microsoft, Facebook and Oracle highlighted as Zacks Bull and Bear of the Day

Zacks Equity Research

The Zacks Analyst Blog Highlights: Guardant, Illumina, Exact Sciences and Pfizer

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Guardant, Illumina, Exact Sciences and Pfizer

Kevin Cook headshot

Bull of the Day: Illumina (ILMN)

by Kevin Cook

The NASA of biotech is helping the world explore crucial genetic information to understand ancestry and disease

Zacks Equity Research

Illumina (ILMN) Down 2.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Illumina (ILMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Tirthankar Chakraborty headshot

3 Stocks to Win Big in the Fight Against Cancer

by Tirthankar Chakraborty

We highlight three stocks that are using innovative ways to treat cancer, also called malignancy. These stocks are also great long-term investments.

Zacks Equity Research

Has Illumina (ILMN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (ILMN) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

GILD vs. ILMN: Which Stock Is the Better Value Option?

by Zacks Equity Research

GILD vs. ILMN: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why You Should Invest in Illumina (ILMN) Stock Now

by Zacks Equity Research

Illumina (ILMN) has been gaining investor confidence on robust performance.

Zacks Equity Research

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Zacks Equity Research

Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (ILMN) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Pacific Biosciences (PACB) Incurs Loss in Q1, Revenues Fall

by Zacks Equity Research

Pacific Biosciences' (PACB) segments see softness in Q1; merger with Illumina on track.

Zacks Equity Research

Illumina (ILMN) Q1 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research

Illumina's (ILMN) NextSeq and MiSeq placements witness year-over-year growth, with the strength of the former being driven by solid demand for TSO500.

Urmimala Biswas headshot

3 Medical Product Stocks Set to Beat This Earnings Season

by Urmimala Biswas

The global medical device space takes significant strides in terms of research and development (R&D) and regulatory progress in the first quarter.

Zacks Equity Research

Analysts Estimate Illumina (ILMN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will Solid Consumables Drive Illumina's (ILMN) Q1 Earnings?

by Zacks Equity Research

Despite ongoing customers' transition from HiSeq consumables to NovaSeq, Illumina's (ILMN) Q1 results are expected to gain from this high throughput suite.

Zacks Equity Research

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Sweta Jaiswal, FRM headshot

Biotechnology Market on a Tear: 5 ETFs in Spotlight

by Sweta Jaiswal, FRM

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.

Sweta Jaiswal, FRM headshot

Global X Launches GNOM ETF to Tap Booming Genomics Space

by Sweta Jaiswal, FRM

Having exposure to trending areas like Robotics & AI, e-commerce and IoT, Global X is set to gain from the booming genomics market with the GNOM ETF.

Zacks Equity Research

Medtronic's New Data for HVAD System to Boost CRHF Segment

by Zacks Equity Research

Medtronic's (MDT) latest data is expected to boost top-line contributions from the HeartWare HVAD System within the CRHF suite.

Zacks Equity Research

Myriad Genetics New Study Data to Lift Prenatal Tests' Uptake

by Zacks Equity Research

The recent development will help Myriad Genetics (MYGN) to boost top-line contributions from prenatal tests.

Zacks Equity Research

Bio-Rad's Latest FDA Nod to Boost Clinical Diagnostics Arm

by Zacks Equity Research

The recent development will help Bio-Rad (BIO) rake in increased top-line contributions from the Clinical Diagnostics business.

Zacks Equity Research

Here's Why You Should Invest in Illumina (ILMN) Stock Now

by Zacks Equity Research

Illumina (ILMN) is currently keeping well with its goals to strengthen foothold in the multi-billion gene sequencing market.